Employer Dropping GLP-1 Coverage in 2027? Your Lowest-Cost Next Steps

If your 2027 open enrollment packet says your employer will stop covering Wegovy or Zepbound for weight loss, start by confirming exactly what is changing, then check whether another covered diagnosis applies, and only then price out the manufacturer's "not covered" offers and self-pay programs. As of October 19, 2026, Lilly lists Zepbound self-pay at $299 to $449 a month by dose, and Novo Nordisk lists Wegovy pens at $349 a month after a $199 introductory price. Both companies say current terms end or will be updated after December 31, 2026, so verify 2027 terms in writing before you plan around them.

Prices recorded October 19, 2026, from manufacturer pages linked below. Prices and terms can change without notice.

How common is this in 2027?

The Business Group on Health surveyed 105 of its employer members in February and March 2026. It found that 67% covered GLP-1s for weight management. Of those, 72% said they were likely to continue that coverage in 2027 and 10% said they likely would not (Business Group on Health, 2026 GLP-1 survey; SHRM).

The same survey lists the tools employers are using instead of a full exclusion: checking clinical eligibility with objective biometric data, requiring a weight management program, limiting who can prescribe, and dropping certain drugs from the formulary. That matters for you, because "we're changing GLP-1 coverage" can mean any of those, not only "we're dropping it."

Step 1: Confirm exactly what is changing

Federal rules require group health plans to give you a Summary of Benefits and Coverage. When you have to fill out enrollment materials, the SBC must come no later than the day those materials go out. When your plan renews automatically, it is due at least 30 days before the new plan year. If a plan makes a material change in the middle of a plan year, it must give notice at least 60 days before the change takes effect (29 CFR 2590.715-2715).

The SBC is a summary. For drug details, you also need the plan's 2027 formulary (drug list) and its exclusions list, usually on the pharmacy benefit manager's website. Look for three different kinds of change:

• Use-based exclusion. The drug stays on the formulary, but "weight loss" or "anti-obesity" use is excluded. Other labeled uses may still be covered with prior authorization.
• Formulary removal. The drug is no longer on the list at all, for any use. A formulary exception may be the only route.
• Tighter criteria. The drug is still covered for weight loss, but with new BMI cutoffs, program enrollment, or prescriber limits.

Questions to ask HR or the plan

1. Is Wegovy or Zepbound excluded for weight loss only, or removed from the 2027 formulary for every use?
2. Will the plan still cover it for cardiovascular risk reduction, MASH, or obstructive sleep apnea, and what are the prior authorization criteria?
3. Is there a transition fill or grandfathering period for people already on the drug?
4. Are diabetes GLP-1s such as Ozempic or Mounjaro affected?
5. Is the plan fully insured or self-funded? (This affects which appeal and state-law rules apply.)

Get the answers in writing, by email or through the plan's member portal, so you have something to point to in January.

Step 2: Check whether another labeled use is still covered

Many plans exclude drugs used for weight loss but cover the same drug when it is prescribed for an FDA-approved medical use. The current labels list these indications:

Source: Wegovy prescribing information (revised 06/2026); Zepbound prescribing information (revised 08/2026).

This only helps if the diagnosis is real and documented in your chart. Asking your prescriber whether one of these uses applies to you is reasonable. Asking them to code a diagnosis you do not have is not, and it can create serious problems for both of you.

Step 3: Know what an appeal can and cannot do

An appeal asks the plan to apply its own rules correctly. If your plan document now excludes anti-obesity drugs, an appeal based only on weight loss usually runs into that written exclusion. Appeals tend to make more sense in two situations:

• You meet the criteria for a covered use (for example, documented sleep apnea or established heart disease) and the plan denied it anyway.
• The drug was removed from the formulary and your prescriber can document why covered alternatives are not appropriate for you. That is usually a formulary exception request, not a standard appeal.

Ask the plan which process applies and what the deadlines are. Keep copies of every denial letter, because the next step often depends on the reason code it lists.

Step 4: Understand how savings cards change when coverage ends

Manufacturer savings cards treat "commercially insured with coverage" and "commercially insured without coverage" as different groups. The 2026 terms are below. All of them exclude Medicare, Medicaid, TRICARE and other government plans.

Source: Lilly, Zepbound coverage and savings; Zepbound savings card terms; Lilly, Mounjaro savings; NovoCare, Wegovy savings offer. Checked October 19, 2026.

Two details trip people up. First, if your plan uses an "alternate funding program" that changes your coverage based on whether a manufacturer card exists, Lilly's terms say you are not eligible for its card (Zepbound terms). Second, Novo says self-pay purchases do not count toward your deductible or out-of-pocket maximum (NovoCare).

Step 5: Run the self-pay math for 2027

If your plan drops coverage and no other use applies, manufacturer self-pay is the main legitimate brand-name option. Here is what the October 2026 prices add up to over 12 months. 2027 prices have not been published, so treat these as a starting point.

Source: LillyDirect, Zepbound self-pay (page updated September 2, 2026); NovoCare, Wegovy. Annual totals are simple multiplication and exclude needles, syringes, taxes and fees.

The cheapest dose is not always the right dose. Lilly notes that 2.5 mg is a starting dose, not a maintenance dose, so plan your budget around the dose you and your prescriber expect to stay on.

Step 6: Decide where HSA or FSA money fits

IRS Publication 502 says prescribed medicines count as medical expenses, and so do amounts paid to lose weight when it is "a treatment for a specific disease diagnosed by a physician" (IRS Publication 502). In practice, that means a prescribed GLP-1 bought through self-pay is generally an eligible expense for a health savings account or flexible spending account. Your account administrator may ask for the prescription or receipt.

Open enrollment is when you set your 2027 FSA election, so a known self-pay cost is worth factoring in now. You can only contribute to an HSA if you are enrolled in an HSA-eligible high-deductible plan.

What to do before January 1

1. Download your 2027 SBC, formulary and exclusions list. Note the exact wording about your drug.
2. Send your plan or HR the questions above and save the written replies.
3. Ask your prescriber whether a labeled non-weight use applies to you and, if so, start prior authorization early.
4. If your card has a December 31, 2026 end date, check the manufacturer site in late December or early January for 2027 terms.
5. If you will self-pay, pick the dose-based monthly price that matches your plan of care and set your FSA election accordingly.
6. Verify every price and term in writing before your first 2027 fill.

Sources

1. Business Group on Health: GLP-1 Costs Loom Large for Employers (2026 survey)
2. SHRM: 1 in 10 Employers Likely Will Stop GLP-1 Coverage in 2027
3. eCFR: 29 CFR 2590.715-2715, Summary of Benefits and Coverage
4. Wegovy Prescribing Information (Novo Nordisk, revised 06/2026)
5. Zepbound Prescribing Information (Eli Lilly, revised 08/2026)
6. Eli Lilly: Zepbound Coverage and Savings
7. Eli Lilly: Zepbound Savings Card Terms and Conditions
8. Eli Lilly: Mounjaro Savings Resources
9. NovoCare: Wegovy Savings Offer
10. LillyDirect: Zepbound Self-Pay Pricing
11. IRS Publication 502: Medical and Dental Expenses

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.